6/29/23, 1:41 AM POP-UP Pathway Feedback Search Clinical Topics Home Studies POP UP POP UP Trial question What is the effect of pantoprazole for stress ulcer prophylaxis in critically ill patients? Study design Single center Double blinded RCT Population Characteristics of study participants 35.0% female N = 214 65.0% male 214 patients (74 female, 140 male) Inclusion criteria: mechanically ventilated critically ill patients suitable for enteral nutrition Key exclusion criteria: acid-suppressive therapy prior to admission, gastrointestinal bleeding, history of proven peptic ulcer disease, administration of > 100 mg daily of prednisolone (or equivalent of other corticosteroid), surgery on the upper gastrointestinal tract or cardiac surgery during the current hospital admission, or pregnancy Interventions N=106 pantoprazole (intravenous infusion of 40 mg in 10 mL of 0.9% saline) N=108 placebo (intravenous infusion of 10 mL of 0.9% saline) Primary outcome Death at 90 days 28.3 % 28.3 23.1 21.2 % 14.2 % 7.1 % https://web.pathway.md/studies/recB640GbRgzfl9QJ 1/2 6/29/23, 1:41 AM POP-UP Pathway No significant difference 0.0 % Pantoprazole Placebo No significant difference in death at 90 days (28.3% vs. 23.1%; aHR 1.68, 95% CI 0.97 to 2.9) Secondary outcomes No significant difference in length of hospital stay (16 days vs. 18 days; AD -2 days, 95% CI -26.07 to 22.07) Safety outcomes No significant differences in ventilator-associated pneumonia, overt bleeding. Conclusion In mechanically ventilated critically ill patients suitable for enteral nutrition, pantoprazole was not superior to placebo with respect to death at 90 days. Reference Selvanderan SP, Summers MJ, Finnis ME et al. Pantoprazole or Placebo for Stress Ulcer Prophylaxis (POP-UP): Randomized Double-Blind Exploratory Study. Crit Care Med. 2016 Oct;44(10):1842-50. Open reference URL https://web.pathway.md/studies/recB640GbRgzfl9QJ 2/2